Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report

J Pharmacol Toxicol Methods. May-Jun 2018;91:36-42. doi: 10.1016/j.vascn.2018.01.003. Epub 2018 Feb 4.

Abstract

Safety pharmacology studies that evaluate drug candidates for potential cardiovascular liabilities remain a critical component of drug development. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have recently emerged as a new and promising tool for preclinical hazard identification and risk assessment of drugs. Recently, Pluriomics organized its first User Meeting entitled 'Combining Pluricyte® Cardiomyocytes & MEA for Safety Pharmacology applications', consisting of scientific sessions and live demonstrations, which provided the opportunity to discuss the application of hiPSC-CMs (Pluricyte® Cardiomyocytes) in cardiac safety assessment to support early decision making in safety pharmacology. This report summarizes the outline and outcome of this Pluriomics User Meeting, which took place on November 24-25, 2016 in Leiden (The Netherlands). To reflect the content of the communications presented at this meeting we have cited key scientific articles and reviews.

Keywords: Cardiotoxicity; Human-induced pluripotent stem cell-derived cardiomyocytes; Multi-electrode array technology; Safety pharmacology.

Publication types

  • Congress

MeSH terms

  • Action Potentials / drug effects*
  • Cardiotoxicity / prevention & control
  • Cell Line
  • Drug Evaluation, Preclinical / instrumentation
  • Drug Evaluation, Preclinical / methods*
  • Drug Evaluation, Preclinical / standards
  • Electrodes
  • Guidelines as Topic
  • Humans
  • Induced Pluripotent Stem Cells / physiology
  • Myocardial Contraction / drug effects
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / physiology
  • Patch-Clamp Techniques / instrumentation
  • Patch-Clamp Techniques / methods